Henry Leder, MD
Uveitis and Ocular Inflammatory Disease · Jacksonville, FLNPI 1275563652
Payments from drug & device makers
Across 160 payments — averaging $118.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Notal Vision, Inc.$5K
- Regeneron Healthcare Solutions, Inc.$357
- Apellis Pharmaceuticals, Inc.$258
- Rxsight Inc$147
- Glaukos Corporation$120
- plus $303 from 6 others
Across 3 payments — averaging $307.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$922
What the payments were for
- Food & beverage$1,203100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $12,500 |
| Notal Vision, Inc. | 131 | $5,298 |
| Regeneron Healthcare Solutions, Inc. | 8 | $357 |
| Apellis Pharmaceuticals, Inc. | 6 | $258 |
| Rxsight Inc | 1 | $147 |
| Glaukos Corporation | 1 | $120 |
| Genentech USA, Inc. | 2 | $80 |
| Bausch & Lomb Americas Inc. | 3 | $74 |
| Mallinckrodt Hospital Products Inc. | 4 | $69 |
| Coherus Oncology, Inc. | 1 | $37 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $25 |
| Alcon | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few uveitis and ocular inflammatory disease providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 134 | $10,088 |
| Difluprednate | 73 | $7,142 |
| Ketorolac Tromethamine | 125 | $5,440 |
| Brimonidine Tartrate | 23 | $2,216 |
| Atropine Sulfate | 29 | $1,723 |
| Mycophenolate Mofetil | 33 | $1,722 |
| Prednisone | 51 | $915 |
| Latanoprost | 36 | $652 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $462 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $354 |
| Dorzolamide Hcl | 14 | $291 |
| Timolol Maleate | 31 | $246 |
Paid to pharmacies, not to this prescriber.
Other uveitis and ocular inflammatory disease in Jacksonville
- Grace Levy-ClarkeTampa$417K
- Maura di NicolaMiami$26K
- Stephanie Llop QuintanaMiami$2K
- Raul Ruiz LozanoMiami$304
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.